To develop effective therapeutic strategies for osteoporosis using IFN-γ, it is critical to investigate the impact of IFN-γ on both the skeletal and immune systems, while taking into account the underlying pathological mechanisms of the disease, and carefully evaluating the optimal dosage, frequency, administration route, and duration of treatment. Here, IFNG is linked to osteoporosis.